Literature DB >> 12454128

Real-time PCR for detection and differentiation of Entamoeba histolytica and Entamoeba dispar in fecal samples.

Joerg Blessmann1, Heidrun Buss, Phuong A Ton Nu, Binh T Dinh, Quynh T Viet Ngo, An Le Van, Mohamed D Abd Alla, Terry F H G Jackson, Jonathan I Ravdin, Egbert Tannich.   

Abstract

A closed-tube, real-time PCR assay was developed for sensitive and specific detection and differentiation of the two closely related intestinal protozoan parasites Entamoeba histolytica and Entamoeba dispar directly from human feces. The assay is performed with the LightCycler system using fluorescence-labeled detection probes and primers amplifying a 310-bp fragment from the high-copy-number, ribosomal DNA-containing ameba episome. The assay was able to detect as little as 0.1 parasite per g of feces. The two pairs of primers used were specific for the respective ameba species, and results were not influenced by the presence of other Entamoeba species even when present in exceeding amounts. PCR was evaluated using several hundred stool samples from areas of amebiasis endemicity in Vietnam and South Africa, and results were compared with those of microscopy and ameba culture. PCR was found to be significantly more sensitive than microscopy or culture, as all samples positive by microscopy and 22 out of 25 (88%) samples positive by culture were also positive by PCR, but PCR revealed a considerable number of additional E. histolytica- or E. dispar-positive samples. Compared to culture and subsequent ameba differentiation by isoenzyme analysis, PCR was 100% specific for each of the two Entamoeba species. Interestingly, the comparison with PCR revealed that culture, in particular, underestimates E. histolytica infections. Given the high sensitivity and specificity of the developed PCR assay, the inability of microscopy to distinguish between the two ameba species, and the time it takes to culture and subsequently differentiate entamoebae by isoenzyme analysis, this assay is more suitable than microscopy or culture to correctly diagnose intestinal E. histolytica or E. dispar infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12454128      PMCID: PMC154634          DOI: 10.1128/JCM.40.12.4413-4417.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  35 in total

1.  Detection of PCR products using self-probing amplicons and fluorescence.

Authors:  D Whitcombe; J Theaker; S P Guy; T Brown; S Little
Journal:  Nat Biotechnol       Date:  1999-08       Impact factor: 54.908

2.  Differentiation of Entamoeba histolytica and Entamoeba dispar using PCR-SHELA and comparison of antibody response.

Authors:  J J Verweij; L van Lieshout; C Blotkamp; E A Brienen; S van Duivenvoorden; M van Esbroeck; A M Polderman
Journal:  Arch Med Res       Date:  2000 Jul-Aug       Impact factor: 2.235

3.  Differentiation of Entamoeba histolytica and Entamoeba dispar cysts using polymerase chain reaction on DNA isolated from faeces with spin columns.

Authors:  J J Verweij; J Blotkamp; E A Brienen; A Aguirre; A M Polderman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-05       Impact factor: 3.267

4.  The LightCycler: a microvolume multisample fluorimeter with rapid temperature control.

Authors:  C T Wittwer; K M Ririe; R V Andrew; D A David; R A Gundry; U J Balis
Journal:  Biotechniques       Date:  1997-01       Impact factor: 1.993

5.  Continuous fluorescence monitoring of rapid cycle DNA amplification.

Authors:  C T Wittwer; M G Herrmann; A A Moss; R P Rasmussen
Journal:  Biotechniques       Date:  1997-01       Impact factor: 1.993

6.  Comparison of the sensitivity of microscopy and culture in the laboratory diagnosis of intestinal protozoal infection.

Authors:  A McMillan; G J McNeillage
Journal:  J Clin Pathol       Date:  1984-07       Impact factor: 3.411

7.  Multiplex polymerase chain reaction amplification and differentiation of Entamoeba histolytica and Entamoeba dispar DNA from stool samples.

Authors:  Y O Núñez; M A Fernández; D Torres-Núñez; J A Silva; I Montano; J L Maestre; L Fonte
Journal:  Am J Trop Med Hyg       Date:  2001 May-Jun       Impact factor: 2.345

8.  Polymerase chain reaction-solution hybridization enzyme-linked immunoassay (PCR-SHELA) for the differential diagnosis of pathogenic and non-pathogenic Entamoeba histolytica.

Authors:  A Aguirre; D C Warhurst; F Guhl; I A Frame
Journal:  Trans R Soc Trop Med Hyg       Date:  1995 Mar-Apr       Impact factor: 2.184

9.  Diagnosis of amoebic infection of the liver: report of 36 cases.

Authors:  H Wynants; J Van den Ende; J Randria; A Van Gompel; E Van den Enden; C Brands; P Coremans; P Michielsen; L Verbist; R Colebunders
Journal:  Ann Soc Belg Med Trop       Date:  1995-12

10.  Epidemiology of amebiasis in a region of high incidence of amebic liver abscess in central Vietnam.

Authors:  Joerg Blessmann; Pham Van Linh; Phuong Anh Ton Nu; Hao Duong Thi; Bertram Muller-Myhsok; Heidrun Buss; Egbert Tannich
Journal:  Am J Trop Med Hyg       Date:  2002-05       Impact factor: 2.345

View more
  47 in total

1.  Diagnosis of amebic liver abscess and amebic colitis by detection of Entamoeba histolytica DNA in blood, urine, and saliva by a real-time PCR assay.

Authors:  Rashidul Haque; Mamun Kabir; Zannatun Noor; S M Mazidur Rahman; Dinesh Mondal; Faisal Alam; Intekhab Rahman; Abdullh Al Mahmood; Nooruddin Ahmed; William A Petri
Journal:  J Clin Microbiol       Date:  2010-06-09       Impact factor: 5.948

Review 2.  Cardiac involvement with parasitic infections.

Authors:  Alicia Hidron; Nicholas Vogenthaler; José I Santos-Preciado; Alfonso J Rodriguez-Morales; Carlos Franco-Paredes; Anis Rassi
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

3.  Evaluation of three diagnostic methods, including real-time PCR, for detection of Dientamoeba fragilis in stool specimens.

Authors:  D Stark; N Beebe; D Marriott; J Ellis; J Harkness
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

Review 4.  Real-time PCR in clinical microbiology: applications for routine laboratory testing.

Authors:  M J Espy; J R Uhl; L M Sloan; S P Buckwalter; M F Jones; E A Vetter; J D C Yao; N L Wengenack; J E Rosenblatt; F R Cockerill; T F Smith
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

5.  Evaluation of Entamoeba histolytica antigen and antibody point-of-care tests for the rapid diagnosis of amebiasis.

Authors:  Megan Leo; Rashidul Haque; Mamun Kabir; Shantanu Roy; Rita Marie Lahlou; Dinesh Mondal; Egbert Tannich; William A Petri
Journal:  J Clin Microbiol       Date:  2006-10-11       Impact factor: 5.948

6.  Mucosal immunity to asymptomatic Entamoeba histolytica and Entamoeba dispar infection is associated with a peak intestinal anti-lectin immunoglobulin A antibody response.

Authors:  Mohamed D Abd-Alla; Terry F G H Jackson; Tyson Rogers; Selvan Reddy; Jonathan I Ravdin
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

7.  Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes.

Authors:  Sa Deepak; Kr Kottapalli; R Rakwal; G Oros; Ks Rangappa; H Iwahashi; Y Masuo; Gk Agrawal
Journal:  Curr Genomics       Date:  2007-06       Impact factor: 2.236

8.  Detection of serum antibody to Entameba histolytica in various population samples of amebic infection using an enzyme-linked immunosorbent assay.

Authors:  A Haghighi; M Rezaeian
Journal:  Parasitol Res       Date:  2005-07-05       Impact factor: 2.289

9.  Entamoeba histolytica and Entamoeba dispar infections in cynomolgus monkeys imported into Japan for research.

Authors:  Jun-ichiro Takano; Toyoko Narita; Hiroshi Tachibana; Toshiyuki Shimizu; Hirofumi Komatsubara; Keiji Terao; Koji Fujimoto
Journal:  Parasitol Res       Date:  2005-07-01       Impact factor: 2.289

10.  Detection and genotyping of Entamoeba histolytica, Entamoeba dispar, Giardia lamblia, and Cryptosporidium parvum by oligonucleotide microarray.

Authors:  Zheng Wang; Gary J Vora; David A Stenger
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.